S&P 500   5,053.38 (-0.17%)
DOW   37,808.60 (+0.19%)
QQQ   431.69 (+0.15%)
AAPL   169.36 (-1.93%)
MSFT   416.14 (+0.60%)
META   500.93 (+0.14%)
GOOGL   154.89 (+0.02%)
AMZN   183.65 (+0.02%)
TSLA   156.52 (-3.07%)
NVDA   873.98 (+1.62%)
AMD   163.23 (+1.82%)
NIO   3.84 (-1.29%)
BABA   70.03 (-0.84%)
T   16.03 (-1.29%)
F   12.18 (-0.41%)
MU   121.04 (-0.27%)
GE   155.81 (+1.37%)
CGC   6.84 (-2.01%)
DIS   114.00 (+0.93%)
AMC   2.86 (+15.79%)
PFE   25.82 (-0.35%)
PYPL   63.92 (+0.65%)
XOM   118.42 (-1.05%)
S&P 500   5,053.38 (-0.17%)
DOW   37,808.60 (+0.19%)
QQQ   431.69 (+0.15%)
AAPL   169.36 (-1.93%)
MSFT   416.14 (+0.60%)
META   500.93 (+0.14%)
GOOGL   154.89 (+0.02%)
AMZN   183.65 (+0.02%)
TSLA   156.52 (-3.07%)
NVDA   873.98 (+1.62%)
AMD   163.23 (+1.82%)
NIO   3.84 (-1.29%)
BABA   70.03 (-0.84%)
T   16.03 (-1.29%)
F   12.18 (-0.41%)
MU   121.04 (-0.27%)
GE   155.81 (+1.37%)
CGC   6.84 (-2.01%)
DIS   114.00 (+0.93%)
AMC   2.86 (+15.79%)
PFE   25.82 (-0.35%)
PYPL   63.92 (+0.65%)
XOM   118.42 (-1.05%)
S&P 500   5,053.38 (-0.17%)
DOW   37,808.60 (+0.19%)
QQQ   431.69 (+0.15%)
AAPL   169.36 (-1.93%)
MSFT   416.14 (+0.60%)
META   500.93 (+0.14%)
GOOGL   154.89 (+0.02%)
AMZN   183.65 (+0.02%)
TSLA   156.52 (-3.07%)
NVDA   873.98 (+1.62%)
AMD   163.23 (+1.82%)
NIO   3.84 (-1.29%)
BABA   70.03 (-0.84%)
T   16.03 (-1.29%)
F   12.18 (-0.41%)
MU   121.04 (-0.27%)
GE   155.81 (+1.37%)
CGC   6.84 (-2.01%)
DIS   114.00 (+0.93%)
AMC   2.86 (+15.79%)
PFE   25.82 (-0.35%)
PYPL   63.92 (+0.65%)
XOM   118.42 (-1.05%)
S&P 500   5,053.38 (-0.17%)
DOW   37,808.60 (+0.19%)
QQQ   431.69 (+0.15%)
AAPL   169.36 (-1.93%)
MSFT   416.14 (+0.60%)
META   500.93 (+0.14%)
GOOGL   154.89 (+0.02%)
AMZN   183.65 (+0.02%)
TSLA   156.52 (-3.07%)
NVDA   873.98 (+1.62%)
AMD   163.23 (+1.82%)
NIO   3.84 (-1.29%)
BABA   70.03 (-0.84%)
T   16.03 (-1.29%)
F   12.18 (-0.41%)
MU   121.04 (-0.27%)
GE   155.81 (+1.37%)
CGC   6.84 (-2.01%)
DIS   114.00 (+0.93%)
AMC   2.86 (+15.79%)
PFE   25.82 (-0.35%)
PYPL   63.92 (+0.65%)
XOM   118.42 (-1.05%)
Free Trial

Aeglea BioTherapeutics (AGLE) Stock Forecast & Price Target

→ Can't believe it's happening again (From Manward Press) (Ad)
Free agle Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media

Aeglea BioTherapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

$17.50
High Forecast$22.50
Average Forecast$17.50
Low Forecast$12.50
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Moderate Buy
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.50$17.50$20.00$46.88
Predicted UpsideN/A32.33% Upside65.75% Upside213.55% Upside
Get Aeglea BioTherapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter.

AGLE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AGLE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Aeglea BioTherapeutics Stock vs. The Competition

TypeAeglea BioTherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside881.92% Upside11.21% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/16/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$8.75 ➝ $12.50+6.84%
7/25/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$22.50+52.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:05 PM ET.

AGLE Price Target - Frequently Asked Questions

What is Aeglea BioTherapeutics's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Aeglea BioTherapeutics stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for AGLE. The average twelve-month price prediction for Aeglea BioTherapeutics is $17.50 with a high price target of $22.50 and a low price target of $12.50. Learn more on AGLE's analyst rating history.

Do Wall Street analysts like Aeglea BioTherapeutics more than its competitors?

Analysts like Aeglea BioTherapeutics less than other Medical companies. The consensus rating score for Aeglea BioTherapeutics is 2.50 while the average consensus rating score for medical companies is 2.68. Learn more on how AGLE compares to other companies.

Does Aeglea BioTherapeutics's stock price have much upside?

According to analysts, Aeglea BioTherapeutics's stock has a predicted upside of 32.33% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:AGLE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Options trading has suddenly become more reliable.
Eagle Publishing
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press